Perioperative toripalimab in non-small cell lung cancer: Clinical outcomes and safety from a large prospective real-world study.

作者
Pingping Song,Jian Zeng,Tianqing Chu,Ying Liu,Zhengliang Tu,Hua Li,Weimin Fang,Shi Yan,Jinyou Liu,LI Yu,Haitao Zhang,Guangjian Zhang,Xi Zhang,Zhengfu He,Xingping Wu,Dongliang Bian,Jie Luo,Chunxia Su,Kun Li,C Chen
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl): 8010-8010
标识
DOI:10.1200/jco.2026.44.16_suppl.8010
摘要

8010 Background: The phase III NEOTORCH trial demonstrated that perioperative toripalimab significantly improved event-free survival in stage IIIA–IIIB driver-gene-negative NSCLC, along with a favorable overall survival trend. However, the generalizability of randomized controlled trial (RCT) results to broader, more heterogeneous, real-world populations is uncertain. This study aimed to evaluate the effectiveness and safety of this regimen in routine clinical practice, providing essential evidence for treatment decisions. Methods: This nationwide, prospective, observational study in China consecutively enrolled patients with stage II-III NSCLC planned for perioperative treatment containing toripalimab. The primary endpoint was real-world event-free survival (rwEFS). Secondary endpoints included pathological complete response (pCR) rate, major pathological response (MPR) rate, objective response rate (ORR), R0 resection rate, real-world disease-free survival (rwDFS), real-world overall survival (rwOS), and safety. Results: Between December 9, 2024, and January 14, 2026, 1727 patients were enrolled from 221 tertiary and secondary hospitals across 28 provinces in China. Baseline characteristics: 82.8% male; 51.4% aged ≥65 years; ECOG PS 0/1/2 in 43.2%/54.4%/2.4%. Histology: 71.4% squamous, 18.3% nonsquamous, 10.3% NSCLC not otherwise specified. Clinical stage distribution: IIA (1.7%), IIB (10.4%), IIIA (52.8%), IIIB (33.0%), IIIC (2.1%). Of all enrolled patients, 542 (31.4%) were pending preoperative assessment. Surgery was not performed in 634 patients (36.7%); reasons included: other causes (64.9%), patient refusal (15.7%), surgical ineligibility (9.3%), disease progression (8.2%), and adverse events (1.9%). Ultimately, 551 patients (31.9%) underwent resection, with 503 having postoperative pathological assessment. The MPR rate was 67.0% (337/503) and the pCR rate was 39.6% (199/503). As of the data-cutoff, investigators reported 20 (1.2%) grade ≥3 or clinically significant treatment-emergent adverse events, with hematologic toxicities being most common. Immune-related adverse events were infrequent (four events: three grade 1–2 pneumonitis, one grade 3 rash). Conclusions: This is the largest prospective real-world study of perioperative immunotherapy in NSCLC to date. Its extensive geographic coverage and diverse patient population-including higher proportions of elderly patients, those with ECOG PS 1, and varied histologies-validate the effectiveness and manageable safety of perioperative toripalimab in routine practice beyond RCT settings. The significant pathological response rates observed support the clinical benefit of this regimen for a broad spectrum of stage II-III NSCLC patients, providing crucial evidence for real-world decision-making. Clinical trial information: ChiCTR2400091457.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
OxO完成签到,获得积分0
刚刚
1秒前
郑关胜发布了新的文献求助30
1秒前
脱羰甲酸发布了新的文献求助10
3秒前
4秒前
5秒前
刘亦菲完成签到,获得积分10
5秒前
音悦台发布了新的文献求助10
6秒前
babyshelling完成签到 ,获得积分10
9秒前
hepingyang发布了新的文献求助10
9秒前
11秒前
blingbling完成签到,获得积分10
12秒前
博纳清发布了新的文献求助10
15秒前
研友_VZG7GZ的应助被布拉布拉采纳,获得10
15秒前
青芸完成签到 ,获得积分10
17秒前
wangpeiyao发布了新的文献求助10
18秒前
DYY完成签到,获得积分10
18秒前
peir完成签到,获得积分10
18秒前
长情小馒头完成签到 ,获得积分10
18秒前
ding的应助被YPHCC采纳,获得10
19秒前
19秒前
Long的应助被褚华健采纳,获得10
19秒前
隐形曼青的应助被8888采纳,获得10
20秒前
情怀的应助被breaking采纳,获得20
22秒前
MISSINGL完成签到 ,获得积分10
24秒前
jiayi发布了新的文献求助10
26秒前
LL发布了新的文献求助10
27秒前
李健的应助被Jason采纳,获得30
27秒前
27秒前
灯火阑珊曦完成签到,获得积分10
27秒前
28秒前
JamesPei的应助被一号采纳,获得10
30秒前
外向大楚完成签到,获得积分10
30秒前
调皮彤完成签到 ,获得积分10
30秒前
红木完成签到 ,获得积分10
31秒前
脱羰甲酸发布了新的文献求助10
31秒前
研究牲完成签到,获得积分10
32秒前
SciGPT的应助被山海不远采纳,获得10
33秒前
8888发布了新的文献求助10
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188371
求助须知:如何正确求助?哪些是违规求助? 9576179
关于积分的说明 21845965
捐赠科研通 7786421
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559601
邀请新用户注册赠送积分活动 2482276